Who should be included in a clinical trial of screening for bladder cancer?
Open Access
Abstract
BACKGROUND: Because of its relatively low incidence, bladder cancer screening might have a better ratio of benefits to harms if it is restricted to a high‐risk population. Data from the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial were used and simple decision analytic techniques were applied to compare different eligibility criteria for a screening trial.METHODS: For a variety of possible eligibility criteria, the percentage of the population aged 55 years to 74 years and classified as being at high risk for developing invasive or high‐grade carcinoma, and therefore likely to benefit from screening, was calculated. Regression models were used to calculate a risk score based on age, sex, smoking history, and family history of bladder cancer. The reduction in cases was calculated given hypothetical risk reductions associated with screening. The trade‐off between patients screened and tumors avoided was calculated as a net benefit.RESULTS: The 5‐year probability of being diagnosed with invasive bladder cancer was 0.24%. Using a risk score > 6 or > 8 as the eligibility criterion for a trial was generally superior to including all older adults. In a typical scenario, a risk score > 6 would result in approximately 25% of the population being screened to prevent 57 invasive or high‐grade bladder cancers per 100,000 population; screening the entire population would prevent only an additional 38 cases.CONCLUSIONS: Screening for bladder cancer can be optimized by restricting it to a subgroup of patients considered to be at elevated risk. Different eligibility criteria for a screening trial can be compared rationally using decision‐analytic techniques. Cancer 2013. © 2012 American Cancer Society.Keywords
This publication has 15 references indexed in Scilit:
- Mortality results from the Göteborg randomised population-based prostate-cancer screening trialThe Lancet Oncology, 2010
- Clinical benefits of a multivariate prediction model for bladder cancerCancer, 2009
- Bladder Cancer Screening in a High Risk Asymptomatic Population Using a Point of Care Urine Based Protein Tumor MarkerJournal of Urology, 2009
- Critical evaluation of urinary markers for bladder cancer detection and monitoring.2008
- Evidence of a Healthy Volunteer Effect in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening TrialAmerican Journal of Epidemiology, 2007
- Long‐term outcome of hematuria home screening for bladder cancer in menCancer, 2006
- Selecting patients for randomized trials: a systematic approach based on risk groupTrials, 2006
- Gender, racial and age differences in bladder cancer incidence and mortalityUrologic Oncology: Seminars and Original Investigations, 2004
- Comparison of bladder cancer outcome in men undergoing hematuria home screening versus those with standard clinical presentationsUrology, 1995
- Dipstick haematuria and bladder cancer in men over 60: results of a community study.BMJ, 1989